一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Pumitamig；Pembrolizumab，当前状态为招募中。登记地点显示中国北京、福州、厦门、漳州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pumitamig；Pembrolizumab · III 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Local Institution - 0175 · 北京
- Fujian Cancer Hospital · 福州
- Local Institution - 0141 · 厦门
- Zhangzhou Municipal Hospital of Fujian Province · 漳州
- Nanfang Medical College Nanfang Hospital · 广州
- Cancer Hospital of Shantou University Medical College · 汕头
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- Local Institution - 0317 · 哈尔滨
- Local Institution - 0046 · 郑州
- Local Institution - 0430 · 武汉
- Local Institution - 0436 · 襄阳
- Local Institution - 0004 · 长沙
- Local Institution - 0435 · 长沙
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School · 南京
- Jiangsu Cancer Hospital · 南京
- The Second Affiliated Hospital of Nanchang University · 南昌
- Local Institution - 0177 · 沈阳
- Local Institution - 0014 · 西安
- Local Institution - 0429 · 济南
- Shandong Cancer Hospital · 济南
- Local Institution - 0123 · 临沂
- Shanghai East Hospital · 上海
- Fudan University-Zhongshan Hospital · 上海
- Sichuan Cancer hospital · 成都
- The Second Affiliated Hospital, Zhejiang University School of Medicine · 杭州
- Sir Run Run Shaw Hospital of Zhejiang University School of Medicine · 杭州
- Local Institution - 0113 · 北京
- Local Institution - 0122 · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Participants must have a histologically or cytologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC) (squamous and nonsquamous) with Stage IIIB/IIIC or Stage IV disease.
- * Participants must have a programmed death ligand-1 (PD-L1) expression ≥ 50%.
- * Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- * Participants must have no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.
- * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
- Exclusion Criteria
- * Participants must not have any documented actionable genomic alteration (AGA) for which first-line (1L) approved therapies are indicated.
- * Participants must not have any symptomatic untreated central nervous system (CNS) metastases, leptomeningeal metastases (carcinomatous meningitis) or spinal cord compression.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07361510；登记信息更新于 2026-09-30；本站同步于 2026-10-08。